Stereotaxis, Inc.
HealthcareAMEX:STXS · New York Stock Exchange American
+$0.02 today
Vol 0.19M · Avg 0.39M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-115.6%
avg -39.2%
ROIC
-72.4%
avg -43.4%
ROA
-41.4%
avg -30.4%
Analysis
ROA is currently the strongest return metric at -41.4% versus its period average of -30.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kimberly R. Peery | Chief Financial Officer | $270,711.00 | — | 57 | $340,750.00 | 0.35% |
David Leo Fischel | Chief Executive Officer & Chairman | $64,390.00 | — | 39 | $677,672.00 | 0.69% |
Keith Galloway | Vice President of Operations | — | — | — | — | — |
Patricia S. Williams | General Counsel & Secretary | — | — | 59 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$66,600.00
Sells
0
$0.00
Net Sentiment
+$66,600.00
Net buying
Most Active
Isaac Paul J
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Nov 17, 2025 | Isaac Paul J Direct | Buy | 10.0K | $2.18 | $21,800.00 | |
| Nov 14, 2025 | Isaac Paul J Indirect | Buy | 20.0K | $2.24 | $44,800.00 |
Analysis
Insiders reported 2 buys worth $66,600.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $66,600.00. Isaac Paul J was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -6.8% | +2.9% (12yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -6.8% over three years. Forward estimates point to Revenue at +2.9% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
NeoGenomics, Inc.
NASDAQ:NEO
$290.37M
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Sanara MedTech Inc.
NASDAQ:SMTI
$190.70M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Quanterix Corporation
QTRX
$146.03M
CVRx, Inc.
CVRX
$133.48M
Exagen Inc.
XGN
$112.83M
MDxHealth S.A.
MDXH
$27.85M
Who manages STXS?
Stereotaxis, Inc. (STXS) lists 4 active executives. The top listed executive is Keith Galloway, Vice President of Operations.
Are STXS insiders buying or selling?
Recent insider activity shows net selling of $14.87M.
Explore More
Continue the stock analysis
Jump to another research area for this company.